MRI Interventions Fresh Insights

It's been a while since we wrote about MRI Interventions (MRIC). We want to share with you two pieces that will enhance your understanding of its potential. 

Kris Tuttle at SoundView Technology Group has updated his research piece on MRIC, and the entire work is exceptional. You can find the presentation below. 

Last week, Voyager Therapeutics (VYGR) posted its April 2018 Corporate presentation to its site. The presentation, which is included at the bottom of this post, highlights the importance of MRIC's ClearPoint system for the delivery of the Voyager Parkinson Payload to the brain. Slides 25-52 contain commentaries on the phase one trial and the posterior approach to delivery. In addition, on page 97, VYGR discusses its goal "to deliver a one-time administration of a 'vectored' monoclonal antibody directed against Tau to potentially treat primary and secondary tauopathies including Alzheimer's disease". 

To think that the MRIC ClearPoint system might be the delivery method for some of the therapeutics developed as part of the VYGR-AbbVie collaboration is really exciting.

MRIC will be presenting at the MicroCap Conference being held in New York City on April 9th and 10th. The conference is free for qualified investors. You can find more at https://microcapconf.com/.

Of interest: 100 to 1 - MRI Interventions, Inc.

Enjoy! 

Michael Bigger. Follow me on Twitter and StockTwits.

MRI Interventions SoundView Note Published Mar 2018 by Research2Zero on Scribd

Voyager Corporate Presentation April 2018 by biggercapital on Scribd

Momentous Alzheimer’s Disease Readouts

Neurotrope (NTRP) will release its Bryostatin Phase 2b top line data this week (company’s guidance). The primary efficacy endpoint is based on Severe Impairment Battery Scale (SIB). Entry criteria was based on the MMSE score. Secondary efficacy endpoints were based on – Activities of Daily Living (ADL), Neuropsychiatric Inventory (NPI), and Mini-Mental State Exam (MMSE).

Considering 70% of all phase two drug trials fail, and even more so with Alzheimer’s Disease (AD) indications, this will be a cage fighting, raw, win or lose, zero or hero event.

We are long NTRP and we wrote about our thesis right here. We are comfortable with our position given our utility curve, our assessment of the situation, its risk and reward potential.

We have the utmost respect for investors going into the event with a short or long position based on their assessment. This is not easy; it shows conviction with a position under imperfect information.

Given the history of AD trials results, it is understandable that many label this situation as a failure from the get go. To be clear, we are handicapping the probability of success and its associated payoff much differently.

ProMIS Neurosciences (PMN.TO) is conducting a cohort study to demonstrate the prevalence of 5 strains (5 epitopes) of soluble toxic oligomers in the cerebrospinal fluid (CSF) of 100 cadavers at the University of British Columbia of patients who had been diagnosed with AD. The results of this study could confirm and present a profile of heterogeneity in AD patients. Based on these results, ProMIS monoclonal antibodies (5 mabs) could be used to create CSF diagnostics for early detection in patients at high risk of the disease.

These mabs could also be used by researchers to advance AD’s science turning PMN’s IPs and therapeutics portfolio into a platform.

The cohort study results should readout before the end of May (our expectation).

In addition, PMN is running blood based screening assays to detect these toxic oligomer strains at the molecular level (5 epitopes). If PMN can overcome the challenges posed by the hypothesis that toxic oligomers have a very short half-life in blood, the company could be in a position to provide a data readout this summer or fall.

We are long ProMIS Neurosciences and we wrote extensively about it here.

Let's Go!

Michael Bigger. Follow me on Twitter and StockTwits.

Disclaimer: We are long the securities and some of their associated derivatives. The likely outcome of an investment in early stage biotech companies is a loss of principal. Take our opinions with a grain of salt. If you find yourself relying on our views to make an investment decision it means you definitely did not do your homework about these situations. Please do not rely on our views, instead use the information as a jumping off point to begin your own independent due diligence.

Neurotrope Tidbits

1. Company Presentation.
2. Bigger Capital Blog Posts: Our Second Alzheimer's Investment: Neurotrope.
3. Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer's Disease including an important comment about safety.
4. Neurotrope Announces Positive Final Results From its Phase 2a Safety Study for the Treatment of Alzheimer's Disease.
5. Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimer's Disease.
6. NCI sponsored clinical trial and FDA Approved Compassionate Use protocols observations.
7. Neurotrope Patents Portfolio.
8. Capital invested in developing Bryostatin (BRNI invested $200 million) and running Neurotrope to date: $250 million.
9. Enterprise value about $25 million.
10. Capital Structure: 7 million shares, 780,000 warrants struck at $44.8, and 3.9 million warants struck at $12.8.
11. PHASE 2b DATA READOUT APRIL 2017.

Of Interest: An Alzheimer's Watershed Event on our Doorstep?

Michael Bigger. Follow me on Twitter and StockTwits.

Disclaimer.